Friday July 24, 5:44 pm Eastern Time
Company Press Release
SOURCE: Lark Technologies, Inc.
Lark Signs Agreement with Pfizer to Establish In-House Contract Service Lab
HOUSTON, July 24 /PRNewswire/ -- Lark Technologies, Inc. (OTC Bulletin Board: LDNA - news) announced it finalized an agreement with Pfizer, Ltd. to
establish an in-house contract service laboratory focused on providing high quality, fast turnaround DNA sequencing services for Pfizer. Lark will provide these
services in a laboratory exclusively dedicated to meeting the DNA sequencing requests of Pfizer at its Sandwich, U.K. facility.
''We are pleased to have been selected by Pfizer to set up this unique service operation,'' stated Mr. Kazmer. ''We believe the agreement represents a win/win
opportunity for both Pfizer and Lark. Pfizer has the benefit of having a high quality service provider in a responsive on-site location and Lark has the ability to
enhance its customer and project base within Pfizer,'' said Mr. Kazmer.
The relationship maintains the integrity of the terms of a contract service provider. Lark will work on behalf of Pfizer for specified fees on a no rights retained,
contract basis. Lark believes this arrangement is particularly attractive for companies like Pfizer who have multiple project needs and require a consistent and reliable
flow of high quality DNA sequence information. ''Lark's professional service expertise is now available for Pfizer in an exclusive satellite operation,'' commented Mr.
Kazmer.
Lark Technologies, Inc., based in Houston, Texas, is a leading molecular biology contract research organization (CRO) serving the rapidly growing genomics
industry. The company was founded in 1989 by BCM Technologies, Inc., the wholly-owned venture, technology transfer subsidiary of Baylor College of Medicine.
Lark's stock is quoted on the NASD's OTC Bulletin Board under the symbol ''LDNA''.
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the ''safe
harbor'' provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause
actual results to differ materially. These forward-looking statements speak only as of the date hereof. Lark disclaims any intent or obligation to update these
forward-looking statements.
SOURCE: Lark Technologies, Inc.
More Quotes and News:
Lark Technologies Inc (OTC BB:LDNA - news)
Related News Categories: medical/pharmaceutical |
